Literature DB >> 1946346

A model for human cardiac troponin C and for modulation of its Ca2+ affinity by drugs.

M Ovaska1, J Taskinen.   

Abstract

Calcium sensitizers are drugs which increase force development in striated muscle by sensitizing myofilaments to Ca2+. This can happen by increasing Ca2+ affinity of the regulatory domain of Ca2+ binding protein troponin C. High resolution crystal structures of two calcium binding proteins, calmodulin (Babu et al.: J. Mol. Biol. 203:191-204, 1988) and skeletal troponin C (Satyshur et al.: J. Biol. Chem. 263:1628-1647, 1988; Herzber et al.: J. Mol. Biol. 203:761-779, 1988), have recently been published. This makes it possible to model in detail the calcium-sensitizing action of drugs on troponin C. In this study a model of human cardiac troponin C in three-calcium state has been constructed. When calcium is bound to calcium site II of cardiac troponin C an open conformation of the protein results, which has a hydrophobic pocket surrounded by a few polar side chains. Complexation of three drugs, trifluoperazine, bepridil, and pimobendan, to the hydrophobic pocket is studied using energy minimization techniques. Two different binding modes are found, which differ in the location of a strong electrostatic interaction. In analogy with the crystal structure of skeletal troponin C it is hypothezed that in cardiac troponin C an interaction occurs between Gln-50 and Asp-88, which has a long-range effect on calcium binding. The binding modes of drugs, where a strong interaction with Asp-88 exists, can effectively prevent the interaction between Asp-88 and Gln-50 in the protein, and are proposed to be responsible for the calcium-sensitizing properties of the studied drugs.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1946346     DOI: 10.1002/prot.340110202

Source DB:  PubMed          Journal:  Proteins        ISSN: 0887-3585


  6 in total

1.  Disparate fluorescence properties of 2-[4'-(iodoacetamido)anilino]-naphthalene-6-sulfonic acid attached to Cys-84 and Cys-35 of troponin C in cardiac muscle troponin.

Authors:  W J Dong; C K Wang; A M Gordon; H C Cheung
Journal:  Biophys J       Date:  1997-02       Impact factor: 4.033

2.  Stage-dependent benefits and risks of pimobendan in mice with genetic dilated cardiomyopathy and progressive heart failure.

Authors:  Miki Nonaka; Sachio Morimoto; Takashi Murayama; Nagomi Kurebayashi; Lei Li; Yuan-Yuan Wang; Masaki Arioka; Tatsuya Yoshihara; Fumi Takahashi-Yanaga; Toshiyuki Sasaguri
Journal:  Br J Pharmacol       Date:  2015-03-17       Impact factor: 8.739

3.  Successful Identification of Cardiac Troponin Calcium Sensitizers Using a Combination of Virtual Screening and ROC Analysis of Known Troponin C Binders.

Authors:  Melanie L Aprahamian; Svetlana B Tikunova; Morgan V Price; Andres F Cuesta; Jonathan P Davis; Steffen Lindert
Journal:  J Chem Inf Model       Date:  2017-11-16       Impact factor: 4.956

4.  Calmidazolium alters Ca2+ regulation of tension redevelopment rate in skinned skeletal muscle.

Authors:  M Regnier; D A Martyn; P B Chase
Journal:  Biophys J       Date:  1996-11       Impact factor: 4.033

Review 5.  The contractile apparatus as a target for drugs against heart failure: interaction of levosimendan, a calcium sensitiser, with cardiac troponin c.

Authors:  Tia Sorsa; Piero Pollesello; R John Solaro
Journal:  Mol Cell Biochem       Date:  2004-11       Impact factor: 3.396

6.  A model for the function of the bisphosphorylated heart-specific troponin-I N-terminus.

Authors:  K Jaquet; K Lohmann; M Czisch; T Holak; J Gulati; R Jaquet
Journal:  J Muscle Res Cell Motil       Date:  1998-08       Impact factor: 2.698

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.